申请人:Pfizer Inc.
公开号:US20040063759A1
公开(公告)日:2004-04-01
A compound of the formula
1
wherein a, b, c R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, Q, W, Y, and Z are defined as above, useful as potent and selective inhibitors of MIP-1&agr; (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
一种化合物,其化学式为1,其中a、b、c、R1、R2、R3、R4、R5、R6、R7、Q、W、Y和Z如上所定义,可用作强效和选择性抑制剂,用于抑制MIP-1α(CCL3)与其受体CCR1结合,CCR1位于炎症和免疫调节细胞上(最好是白细胞和淋巴细胞)。